FLT3/NPM1 mutation testing

Alphabetical Test listing

FLT3/NPM1 mutation testing-8152

  
FLT3/NPM1 mutation testing
  
8152
  
LAB8152
  
FLT3/NPM1 MU
  
FLT3 ITD
FLT3 TKD (D835)
Nucleophosmin
  

This is a qualitative assay intended to aid in the characterization of Acute Myelogenous Leukemia (AML), which may affect treatment options.

This assay should not be used to monitor minimal residual disease.

  
EDTA whole blood
  
  
4.0 mL
  
1.0 mL
  
  1. Mix tube immediately upon collection
  2. Submit tube unspun
  

Lavender (EDTA), 4mL

  
Sodium citrate (NaCit) whole blood
ACD whole blood
Bone marrow in EDTA
  

Lt blue Sodium citrate (NaCit)

Yellow ACD (A or B)

 

Bone Marrow:

Lavender (EDTA), 4mL

  
Bone marrow - 1.0 mL
  

Lt blue Sodium citrate (NaCit)

Yellow ACD (A or B)

Bone marrow:

Lavender (EDTA), 4mL

  

Molecular Medicare billing request

Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medical billing request form along with the sample.

  • Complete and submit the form to notify us of the need for Allina Health Laboratory to bill insurance for Molecular testing performed
  • All information requested is required in order for your request to be completed
  

Ambient (preferred)

Refrigerated

  
  • Improper label (unlabeled or mislabeled)
  • Wrong container (anticoagulant or solution)
  • Improper blood/anticoagulant ratio
  • Delay in transport
  • Improper storage
  • Inappropriate timing of collection
  • Interfering substances
  • Leaking container
  
AHL - Molecular Diagnostics: D
  
Varies
  
7 days
  

Polymerase Chain Reaction (PCR) & Capillary electrophoresis

  

Not detected

  

This assay should not be used to monitor minimal residual disease (sensitivity 5% allele fraction).

  
This test may require preauthorization from the insurance provider. Check the payer guidelines and, if needed, obtain the pre-authorization prior to sample collection.
  
81245
81246
81310
  
Yes
  
  
01/17/2017
  
07/27/2018
  
03/13/2020